Acadia Pharmaceuticals
ACAD
237 hedge funds and large institutions have $2.41B invested in Acadia Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 77 increasing their positions, 82 reducing their positions, and 37 closing their positions.
168% more call options, than puts
Call options by funds: $22M | Put options by funds: $8.23M
6% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 82
2.28% less ownership
Funds ownership: 92.44% → 90.16% (-2.3%)
3% less funds holding
Funds holding: 245 → 237 (-8)
19% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 37
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
33% less capital invested
Capital invested by funds: $3.61B → $2.41B (-$1.2B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$33.9M |
| 2 |
D.E. Shaw & Co
New York
|
+$15.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$12.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$68.5M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$24.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$17.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.8M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$12.7M |
ACAD Hedge Fund Activity: Q3 2021 in Review
237 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2021, worth a combined $2.41B — down 33% from $3.61B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ACAD and 30 opened new positions — a net loss of 7 holders — while 82 trimmed existing stakes and 77 added.
The largest buyer was State Street, adding an estimated $33.9M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $68.5M sold.
- 237 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2021, down from 245 in Q2 2021.
- Funds reported $2.41B of Acadia Pharmaceuticals stock for Q3 2021, down 33% quarter-over-quarter.
- 30 funds opened new Acadia Pharmaceuticals positions in Q3 2021 and 37 closed out, a net change of -7 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2021 was State Street, an estimated $33.9M added.
- The largest Acadia Pharmaceuticals seller in Q3 2021 was PFM Health Sciences, an estimated $68.5M sold.
Based on aggregated 13F filings for Q3 2021.